Artivion Reports Strong Q1 Revenue Growth and $135M Acquisition of Endospan

Key Facts

1Artivion achieved revenue of $116.3 million in Q1 2026, an 18% increase year-over-year.

2The company exercised its option to acquire Endospan for an upfront purchase price of $135 million.

3The company's NEXUS Aortic Arch System received U.S. FDA PMA approval.

Artivion, Inc. reported robust financial results for the first quarter of 2026, with revenue reaching $116.3 million, an 18% increase year-over-year. Alongside the earnings growth, the company exercised its option to acquire Endospan for an upfront purchase price of $135 million. The company also achieved a major regulatory milestone as its NEXUS Aortic Arch System received U.S. FDA PMA approval. This strategic expansion is supported by a 26% jump in adjusted EBITDA, showcasing strong operational execution. The acquisition and product approvals are expected to significantly enhance Artivion's competitive position in the cardiac and vascular surgery markets. These developments represent significant positive catalysts for the company's mid-term growth trajectory.